FR13C0013I1 - - Google Patents
Info
- Publication number
- FR13C0013I1 FR13C0013I1 FR13C0013C FR13C0013I1 FR 13C0013 I1 FR13C0013 I1 FR 13C0013I1 FR 13C0013 C FR13C0013 C FR 13C0013C FR 13C0013 I1 FR13C0013 I1 FR 13C0013I1
- Authority
- FR
- France
- Prior art keywords
- glucagon
- analogs
- peptide
- synthesis
- identified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63127396A | 1996-04-12 | 1996-04-12 | |
PCT/CA1997/000252 WO1997039031A1 (en) | 1996-04-12 | 1997-04-11 | Glucagon-like peptide-2 analogs |
Publications (2)
Publication Number | Publication Date |
---|---|
FR13C0013I1 true FR13C0013I1 (ja) | 2013-05-04 |
FR13C0013I2 FR13C0013I2 (fr) | 2013-08-16 |
Family
ID=24530501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR13C0013C Active FR13C0013I2 (fr) | 1996-04-12 | 2013-02-22 | Analogues de peptide 2 du type glucagon |
Country Status (16)
Country | Link |
---|---|
EP (5) | EP2009024A1 (ja) |
JP (3) | JP4148994B2 (ja) |
CN (1) | CN1268640C (ja) |
AT (2) | ATE227309T1 (ja) |
AU (1) | AU733857B2 (ja) |
BR (1) | BRPI9708566B8 (ja) |
CA (1) | CA2251576C (ja) |
DE (2) | DE69716905T2 (ja) |
DK (2) | DK0906338T3 (ja) |
ES (2) | ES2351661T3 (ja) |
FR (1) | FR13C0013I2 (ja) |
HK (3) | HK1033324A1 (ja) |
LU (1) | LU92153I2 (ja) |
NZ (1) | NZ332281A (ja) |
PT (2) | PT906338E (ja) |
WO (1) | WO1997039031A1 (ja) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
AU733857B2 (en) * | 1996-04-12 | 2001-05-31 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
CA2236519C (en) | 1997-05-02 | 2011-09-13 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
DK0981362T3 (da) * | 1997-05-16 | 2004-03-15 | Ontario Inc 1149336 | Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal |
WO1999043361A1 (en) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
WO1999058144A1 (en) * | 1998-05-11 | 1999-11-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
WO2002022151A2 (en) | 2000-09-18 | 2002-03-21 | Osteometer Bio Tech A/S | Use of glp-1 and flp-2 peptides for treatment of bone disorders |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
WO2004035624A2 (en) * | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
EP1592471B1 (en) | 2003-02-04 | 2011-03-23 | Novo Nordisk A/S | Injection device with rotatable dose setting mechanism |
EP1664109B1 (en) * | 2003-08-21 | 2009-07-22 | Novo Nordisk A/S | Purification of glucagon-like peptides |
ATE550041T1 (de) | 2004-01-21 | 2012-04-15 | Novo Nordisk Healthcare Ag | Transglutaminase-vermittelte konjugation von peptiden |
EP1809318B1 (en) * | 2004-11-01 | 2013-06-12 | NPS Pharmaceuticals, Inc. | Treatment of short bowel syndrome patients with colon-in-continuity |
BRPI0610091B1 (pt) | 2005-05-04 | 2021-08-03 | Zealand Pharma A/S | Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico |
CN100418983C (zh) * | 2005-05-11 | 2008-09-17 | 中国药科大学 | 人胰高血糖素相关肽-2类似物 |
CN101573376B (zh) | 2006-11-08 | 2013-11-06 | 西兰制药公司 | 选择性胰高血糖素样肽-2(glp-2)类似物 |
CN102942626B (zh) * | 2009-03-05 | 2015-11-04 | 江苏豪森医药集团有限公司 | 胰高血糖素样肽-2类似物及其制备方法和用途 |
EP2311486A1 (en) * | 2009-10-07 | 2011-04-20 | Nestec S.A. | GLP-2 for use in intestine and muscle recovery |
EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
BR112012011467A2 (pt) * | 2009-10-30 | 2019-09-24 | Otsuka Chemical Co Ltd | forma glicosilada de análogo ao glp-1 antigênico. |
US9782454B2 (en) | 2010-04-22 | 2017-10-10 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
EP2569001A4 (en) * | 2010-05-11 | 2014-06-25 | Nps Pharma Inc | PROCEDURE FOR TREATING OR PREVENTING KIDNEY OR REFUSE FUNCTIONS |
EP2694083A2 (en) | 2011-04-01 | 2014-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders |
CN102924589B (zh) * | 2011-08-11 | 2016-08-24 | 中肽生化有限公司 | 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途 |
TR201802689T4 (tr) | 2012-05-03 | 2018-03-21 | Zealand Pharma As | Glukagon benzeri peptit-2 (glp-2) analogları. |
CN103159848B (zh) * | 2013-01-06 | 2015-11-25 | 中国人民解放军第四军医大学 | 人胰高血糖素样肽-2二串体蛋白及其制备方法 |
US9789164B2 (en) | 2013-03-15 | 2017-10-17 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
US10774127B2 (en) * | 2016-10-12 | 2020-09-15 | University Of Copenhagen | Peptide dual agonists of GIPR and GLP2R |
JP6563614B1 (ja) | 2016-12-09 | 2019-08-21 | ジーランド・ファーマ・ア/エス | アシル化glp−1/glp−2二重アゴニスト |
WO2019086559A1 (fr) | 2017-10-31 | 2019-05-09 | Adocia | Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
WO2020020904A1 (en) | 2018-07-23 | 2020-01-30 | Zealand Pharma A/S | Therapeutic uses of glp-2 agonists |
EP3628682A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
EP3628683A1 (en) | 2018-09-28 | 2020-04-01 | Zealand Pharma A/S | Formulations of glucagon-like-peptide-2 (glp-2) analogues |
KR20210126088A (ko) | 2019-02-11 | 2021-10-19 | 옵코 바이오로직스 리미티드 | 지속성 glp-2 유사체 |
WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
EP4126004A1 (en) | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Agonist combination |
WO2023111273A1 (en) * | 2021-12-17 | 2023-06-22 | Bainan Biotech Aps | Peptide dual agonists of gipr and glp2r |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5186117A (en) | 1975-01-27 | 1976-07-28 | Tanabe Seiyaku Co | Johoseibiryushiseizainoseiho |
GB1575343A (en) | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
US4529561A (en) | 1978-03-24 | 1985-07-16 | The Regents Of The University Of California | Method for producing liposomes in selected size range |
GB2046092B (en) | 1979-03-05 | 1983-11-02 | Toyama Chemical Co Ltd | Pharmaceutical composition containing a lysophospholid and a phospholipid |
US4452747A (en) | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
US4725442A (en) | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
US4921706A (en) | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US5009956A (en) | 1987-02-24 | 1991-04-23 | Univ Minnesota | Phospholipase A2-resistant liposomes |
US4927637A (en) | 1989-01-17 | 1990-05-22 | Liposome Technology, Inc. | Liposome extrusion method |
US4944948A (en) | 1989-02-24 | 1990-07-31 | Liposome Technology, Inc. | EGF/Liposome gel composition and method |
JP2961045B2 (ja) * | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
EP0658568A1 (en) | 1993-12-09 | 1995-06-21 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
AU710818B2 (en) | 1996-03-01 | 1999-09-30 | Novo Nordisk A/S | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
AU733857B2 (en) | 1996-04-12 | 2001-05-31 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
-
1997
- 1997-04-11 AU AU25002/97A patent/AU733857B2/en not_active Expired
- 1997-04-11 JP JP53660897A patent/JP4148994B2/ja not_active Expired - Lifetime
- 1997-04-11 EP EP08154386A patent/EP2009024A1/en not_active Withdrawn
- 1997-04-11 EP EP10163303.0A patent/EP2218734B1/en not_active Expired - Lifetime
- 1997-04-11 BR BRPI9708566A patent/BRPI9708566B8/pt active IP Right Grant
- 1997-04-11 DE DE69716905T patent/DE69716905T2/de not_active Expired - Lifetime
- 1997-04-11 ES ES01129072T patent/ES2351661T3/es not_active Expired - Lifetime
- 1997-04-11 NZ NZ332281A patent/NZ332281A/xx not_active IP Right Cessation
- 1997-04-11 WO PCT/CA1997/000252 patent/WO1997039031A1/en active IP Right Grant
- 1997-04-11 CN CNB971953317A patent/CN1268640C/zh not_active Expired - Lifetime
- 1997-04-11 EP EP97916280A patent/EP0906338B1/en not_active Expired - Lifetime
- 1997-04-11 ES ES97916280T patent/ES2188929T3/es not_active Expired - Lifetime
- 1997-04-11 EP EP10012937A patent/EP2275438A1/en not_active Withdrawn
- 1997-04-11 PT PT97916280T patent/PT906338E/pt unknown
- 1997-04-11 AT AT97916280T patent/ATE227309T1/de active
- 1997-04-11 CA CA2251576A patent/CA2251576C/en not_active Expired - Lifetime
- 1997-04-11 AT AT01129072T patent/ATE478892T1/de active
- 1997-04-11 EP EP01129072A patent/EP1231219B1/en not_active Expired - Lifetime
- 1997-04-11 DK DK97916280T patent/DK0906338T3/da active
- 1997-04-11 DE DE60142885T patent/DE60142885D1/de not_active Expired - Lifetime
- 1997-04-11 DK DK01129072.3T patent/DK1231219T3/da active
-
2000
- 2000-08-15 HK HK00105089A patent/HK1033324A1/xx not_active IP Right Cessation
-
2001
- 2001-12-07 PT PT01129072T patent/PT1231219E/pt unknown
-
2003
- 2003-02-07 HK HK11101311.7A patent/HK1147761A1/xx not_active IP Right Cessation
- 2003-02-07 HK HK03100905.1A patent/HK1050204B/zh not_active IP Right Cessation
-
2007
- 2007-04-24 JP JP2007114302A patent/JP4149497B2/ja not_active Expired - Lifetime
-
2008
- 2008-02-07 JP JP2008027918A patent/JP5019466B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-19 LU LU92153C patent/LU92153I2/fr unknown
- 2013-02-22 FR FR13C0013C patent/FR13C0013I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR13C0013I1 (ja) | ||
HUT64298A (en) | Method for producing 9-amino-7-(substituted)-6-demethyl-6-desoxy-0tetracycline derivatives and medical preparatives containing them | |
NO944644D0 (no) | Fremstilling av 3,4,4-trisubstituert-piperidinyl-N-alkylkarboksylater og mellomprodukter | |
MX9605206A (es) | 1alfa,26-dihidroxi-d-homo-vitamina d3. | |
HU9601857D0 (en) | New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them | |
HU902288D0 (en) | Process for producing new epimers of 1-alpha-hydroxy-d vitamin and their derivatives as well as pharmaceutical preparatives containing these compounds | |
AU7880494A (en) | 5-methyluridine process for large-scale preparation of 2',3'-didehydro-3'-deoxythymidine (d4T) | |
MX9803672A (es) | Nuevos derivados de fenilamidina, procedimiento para su preparacion y su utilizacion como medicamentos. | |
MY106522A (en) | Arylaminocarbonyl compounds. | |
HU910506D0 (en) | Process for producing 20, 21-dinoreburnamenine derivatives substituted inthe 9,10 and/or 11-location and pharmaceutical preparatives containing said compounds | |
ATE253902T1 (de) | Arzneistoffe zur selektiven bekämpfung von tumorgewebe | |
EP0034647A3 (en) | 4-aryloxy- and 4-arylthio-3-phenylpiperidine derivatives, a process for the preparation of such compounds and their use as medicaments | |
HU9203928D0 (en) | 6-sulfonyl-substituted 3-hydroxi-chromane derivatives and pharmaceutical preparatives containing them | |
MX9602804A (es) | Derivados del 3-aril-alquenil-1,2,4-oxadiazol y su uso como parasiticidas para animales. | |
AU8516991A (en) | Arg a human gene related to but distinct from abl proto-oncogene | |
EP0641335A4 (en) | SYNTHESIS OF BENZOPROSTACYCLINES CATALYZED BY FREE RADICALS. | |
HU910463D0 (en) | Process for the production of medical preparation | |
HUP9600476A3 (en) | Benzothiophene compounds, intermediates, process for their production, their use and compositions containing them | |
AU634635C (en) | 1-alkyl-, 1-alkenyl- and 1-alkynylaryl-2-amino-1,3- propanediols and related compounds, a process and intermediates for their preparation and their use as medicaments | |
YU16590A (en) | Process for preparing cyclical derivatives of 2',3'-seco-uridine | |
HU903473D0 (en) | Process for the production of beta-cyclodextrine based inclusion as a medical product | |
ZA923165B (en) | Novel anthelmintic milbemycin analogs of novel microorganisms | |
MN426A8 (en) | Preparation of lactic-acidic product vitaminized by b12 using propion-acidic p.shermani bacteria | |
ZA911805B (en) | 1-alkyl-,1 alkenyl-and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds,a process and intermediates for their preparation and their use as medicaments |